{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:58:46Z","timestamp":1792277926442,"version":"4.4.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ctrv.2022.102497","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T11:07:33Z","timestamp":1670670453000},"page":"102497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Low grade serous ovarian cancer \u2013 A rare disease with increasing therapeutic options"],"prefix":"10.1016","volume":"112","author":[{"given":"Tibor A.","family":"Zwimpfer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ori","family":"Tal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Rimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Heinzelmann-Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2022.102497_b0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.pgp.0000101080.35393.16","article-title":"The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin","volume":"1","author":"Seidman","year":"2004","journal-title":"Int J Gynecol Pathol"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102497_b0010","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal Maintenance Therapy for Women with Low-Grade Serous Cancer of the Ovary or Peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102497_b0015","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ygyno.2016.08.320","article-title":"Low-grade serous ovarian cancer: A review","volume":"143","author":"Kaldawy","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102497_b0020","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/PGP.0b013e31827630eb","article-title":"Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry","volume":"32","author":"Ali","year":"2013","journal-title":"Int J Gynecol Pathol"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102497_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2008.01.035","article-title":"Epidemiology of low-grade serous ovarian cancer","volume":"198","author":"Plaxe","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"21","key":"10.1016\/j.ctrv.2022.102497_b0030","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2022.102497_b0035","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1093\/annonc\/mdw089","article-title":"The molecular pathology of ovarian serous borderline tumors","volume":"27 Suppl 1","author":"Malpica","year":"2016","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102497_b0040","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1002\/cncr.26618","article-title":"Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study","volume":"118","author":"Bodurka","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102497_b0045","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102497_b0050","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/pgp.0b013e31803025cd","article-title":"Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis","volume":"26","author":"Wong","year":"2007","journal-title":"Int J Gynecol Pathol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102497_b0055","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ygyno.2012.10.013","article-title":"Quantification of ER\/PR expression in ovarian low-grade serous carcinoma","volume":"128","author":"Escobar","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102497_b0060","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102497_b0065","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102497_b0070","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant","volume":"114","author":"Gershenson","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102497_b0075","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","article-title":"Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary","volume":"108","author":"Gershenson","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102497_b0080","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ygyno.2020.06.498","article-title":"The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: further evidence of relative chemoresistance","volume":"158","author":"Cobb","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102497_b0085","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/IGC.0000000000000977","article-title":"Efficacy of Pegylated Liposomal Doxorubicin in Low-Grade Serous Ovarian Carcinoma","volume":"27","author":"Rose","year":"2017","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102497_b0090","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.ctrv.2022.102497_b0095","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.ctrv.2022.102497_b0100","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum- resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial","volume":"33","author":"Poveda","year":"2015","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2022.102497_b0105","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102497_b0110","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease\u2020","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102497_b0115","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/IGC.0000000000000190","article-title":"Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer","volume":"24","author":"Grisham","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102497_b0120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ygyno.2017.01.027","article-title":"Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience","volume":"145","author":"Dalton","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102497_b0125","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1097\/IGC.0000000000000742","article-title":"Activity of Bevacizumab in Patients With Low-Grade Serous Ovarian Carcinoma","volume":"26","author":"Rose","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102497_b0130","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/14737140.2017.1272414","article-title":"Endocrine therapy in epithelial ovarian cancer","volume":"17","author":"Langdon","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102497_b0135","first-page":"2233","article-title":"CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup","volume":"8","author":"Bowman","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102497_b0140","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ygyno.2012.02.037","article-title":"Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum","volume":"125","author":"Gershenson","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102497_b0145","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1158\/1078-0432.CCR-06-2878","article-title":"Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients","volume":"13","author":"Smyth","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102497_b0150","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ygyno.2017.02.029","article-title":"Hormone receptor expression profile of low-grade serous ovarian cancers","volume":"145","author":"Buttarelli","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102497_b0155","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13048-016-0300-5","article-title":"Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC)","volume":"10","author":"Feng","year":"2017","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.ctrv.2022.102497_b0160","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.humpath.2018.10.020","article-title":"Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network","volume":"85","author":"Sehouli","year":"2019","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102497_b0165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2019.11.029","article-title":"Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma","volume":"157","author":"Llaurado Fernandez","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102497_b0170","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2017.07.127","article-title":"Primary cytoreductive surgery and adjuvant low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?","volume":"147","author":"Fader","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102497_b0175","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.1999.17.2.460","article-title":"Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy","volume":"17","author":"Kuerer","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102497_b0180","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s12916-015-0472-7","article-title":"Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes - what does it all mean?","volume":"13","author":"Earl","year":"2015","journal-title":"BMC Med"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102497_b0185","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1093\/annonc\/mdq072","article-title":"Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer","volume":"21","author":"Cancello","year":"2010","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102497_b0190","doi-asserted-by":"crossref","first-page":"e7695","DOI":"10.1371\/journal.pone.0007695","article-title":"Breast cancer in young women: poor survival despite intensive treatment","volume":"4","author":"Fredholm","year":"2009","journal-title":"PLoS One"},{"issue":"24","key":"10.1016\/j.ctrv.2022.102497_b0195","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1200\/JCO.2015.61.0873","article-title":"Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor","volume":"33","author":"Gershenson","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2022.102497_b0200","doi-asserted-by":"crossref","first-page":"TPS5598","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5598","article-title":"ENGOT-ov54\/Swiss-GO-2\/MATAO including LOGOS (Low-Grade Ovarian cancer Sub-study): MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer\u2014A randomized, double-blinded, placebo-controlled, multicenter phase III Trial","volume":"39","author":"Heinzelmann-Schwarz","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102497_b0205","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-09555-8","article-title":"Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial","volume":"22","author":"McLaughlin","year":"2022","journal-title":"BMC Cancer"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2022.102497_b0210","doi-asserted-by":"crossref","first-page":"TPS5601","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5601","article-title":"A randomized phase III, two-arm trial of paclitaxel, carboplatin, and maintenance letrozole versus letrozole monotherapy in patients with stage II-IV, primary low-grade serous carcinoma of the ovary or peritoneum","volume":"39","author":"Nickles Fader","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102497_b0215","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","article-title":"Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma","volume":"95","author":"Singer","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102497_b0220","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0002-9440(10)62549-7","article-title":"Diverse tumorigenic pathways in ovarian serous carcinoma","volume":"160","author":"Singer","year":"2002","journal-title":"Am J Pathol"},{"issue":"22","key":"10.1016\/j.ctrv.2022.102497_b0225","doi-asserted-by":"crossref","first-page":"10602","DOI":"10.1158\/0008-5472.CAN-05-2240","article-title":"Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary","volume":"65","author":"Bonome","year":"2005","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102497_b0230","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2353\/ajpath.2010.100212","article-title":"BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas","volume":"177","author":"Wong","year":"2010","journal-title":"Am J Pathol"},{"issue":"19","key":"10.1016\/j.ctrv.2022.102497_b0235","doi-asserted-by":"crossref","first-page":"6432","DOI":"10.1158\/1078-0432.CCR-04-0893","article-title":"Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas","volume":"10","author":"Hsu","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102497_b0240","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol"},{"issue":"32","key":"10.1016\/j.ctrv.2022.102497_b0245","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.20.01164","article-title":"MILO\/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum","volume":"38","author":"Monk","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10324","key":"10.1016\/j.ctrv.2022.102497_b0250","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102497_b0255","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1158\/1535-7163.MCT-17-1177","article-title":"Adaptive Resistance to Chemotherapy, A Multi-FAK-torial Linkage","volume":"17","author":"Taylor","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2022.102497_b0260","doi-asserted-by":"crossref","unstructured":"Banerjee SN, Monk BJ, Nieuwenhuysen EV, Moore KN, Oaknin A, Fabbro M, et al. ENGO-ov60\/GOG3052\/RAMP 2021: A phase 2 study of VS-6766 (dual RAF\/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor(in recurrent low-grade serous ovarian cancer (LGSOC). J Clin Oncol 2021;39:15_suppl, TPS5603-TPS56603 https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.TPS5603.","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5603"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102497_b0265","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11864-018-0571-8","article-title":"Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions","volume":"19","author":"Grisham","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ctrv.2022.102497_b0270","doi-asserted-by":"crossref","unstructured":"Sadlecki P, Walentowicz P, Bodnar M, Marszalek A, Grabiec M, Walentowicz-Sadlecka M. Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers. Tumour Biol 2017;39(5):1010428317706230. https:\/\/doi.org\/10.1177\/1010428317706230.","DOI":"10.1177\/1010428317706230"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102497_b0275","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/his.13651","article-title":"BRAFV600E mutations and immunohistochemical expression of VE1 protein in low-grade serous neoplasms of the ovary","volume":"73","author":"Turashvili","year":"2018","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102497_b0280","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cncr.27782","article-title":"BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer","volume":"119","author":"Grisham","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102497_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00221","article-title":"BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition","author":"Moujaber","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2022.102497_b0290","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.gore.2018.09.002","article-title":"Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation","volume":"26","author":"Mendivil","year":"2018","journal-title":"Gynecol Oncol Rep"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102497_b0295","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/03009734.2020.1826612","article-title":"Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma","volume":"125","author":"Tholander","year":"2020","journal-title":"Ups J Med Sci"},{"issue":"19","key":"10.1016\/j.ctrv.2022.102497_b0300","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1200\/JCO.19.02654","article-title":"Phase I, Open-Label, Dose-Escalation\/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors","volume":"38","author":"Desai","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102497_b0305","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40265-018-0884-8","article-title":"BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers","volume":"78","author":"Sanchez","year":"2018","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102497_b0310","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1055\/s-0043-118907","article-title":"PI3K\/AKT\/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?","volume":"77","author":"Gasparri","year":"2017","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1016\/j.ctrv.2022.102497_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102021","article-title":"Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer","volume":"86","author":"Huang","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102497_b0320","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/path.3967","article-title":"Low-grade serous carcinomas of the ovary contain very few point mutations","volume":"226","author":"Jones","year":"2012","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102497_b0325","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5732\/cjc.014.10289","article-title":"The PI3K\/Akt\/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges","volume":"34","author":"Cheaib","year":"2015","journal-title":"Chin J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102497_b0330","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/diagnostics10010013","article-title":"High Frequency of PIK3CA Mutations in Low-Grade Serous Ovarian Carcinomas of Japanese Patients","volume":"10","author":"Ishibashi","year":"2019","journal-title":"Diagnostics (Basel)"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102497_b0335","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3390\/cancers11070949","article-title":"PI3K-AKT-mTOR and NF\u03baB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics","volume":"11","author":"Ghoneum","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2022.102497_b0340","doi-asserted-by":"crossref","unstructured":"Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566-1576. https:\/\/doi.org\/10.1007\/s00125-017-4318-z.","DOI":"10.1007\/s00125-017-4318-z"},{"key":"10.1016\/j.ctrv.2022.102497_b0345","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","article-title":"Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance","volume":"59","author":"Ediriweera","year":"2019","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102497_b0350","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/cncr.27706","article-title":"Metformin intake is associated with better survival in ovarian cancer: a case-control study","volume":"119","author":"Kumar","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2022.102497_b0355","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1582-4934.2009.00954.x","article-title":"Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner","volume":"15","author":"Rattan","year":"2011","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.ctrv.2022.102497_b0360","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1593\/neo.11148","article-title":"Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo","volume":"13","author":"Rattan","year":"2011","journal-title":"Neoplasia"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102497_b0365","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ygyno.2017.05.019","article-title":"Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer","volume":"146","author":"Mert","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102497_b0370","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ygyno.2019.12.002","volume":"156","author":"Arend","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2022.102497_b0375","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.canlet.2019.10.021","article-title":"MiR-337-3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB","volume":"469","author":"Zhang","year":"2020","journal-title":"Cancer Lett"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102497_b0380","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1158\/1078-0432.CCR-10-2307","article-title":"Expression of p16 and retinoblastoma determines response to CDK4\/6 inhibition in ovarian cancer","volume":"17","author":"Konecny","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2022.102497_b0385","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrm3567","article-title":"Molecular mechanisms underlying RB protein function","volume":"14","author":"Dick","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2022.102497_b0390","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nrm3629","article-title":"Control of cell cycle transcription during G1 and S phases","volume":"14","author":"Bertoli","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102497_b0395","first-page":"901","article-title":"Mechanisms of the CDK4\/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (Review)","volume":"39","author":"Liu","year":"2018","journal-title":"Oncol Rep"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102497_b0400","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1080\/03007995.2017.1348344","article-title":"A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer","volume":"33","author":"Bilgin","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102497_b0405","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.3390\/cancers13123035","article-title":"Inhibition of CDK4\/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives","volume":"13","author":"Dall'Acqua","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102497_b0410","doi-asserted-by":"crossref","first-page":"e000926","DOI":"10.1136\/esmoopen-2020-000926","article-title":"Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers","volume":"5","author":"Colon-Otero","year":"2020","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102497_b0415","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2022.102497_b0420","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1200\/JCO.2022.40.16_suppl.5522","article-title":"A pilot phase II study of neodjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma","volume":"40","author":"Cobb","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102497_b0425","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ygyno.2021.10.080","article-title":"Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis","volume":"164","author":"Goldberg","year":"2022","journal-title":"Gynecol Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:27:31Z","timestamp":1759656451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737222001736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":85,"alternative-id":["S0305737222001736"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102497","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low grade serous ovarian cancer \u2013 A rare disease with increasing therapeutic options","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102497"}}